Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Evolocumab is a prescription monoclonal antibody and PCSK9 inhibitor sold in the United States as Repatha. It reduces major cardiovascular events in adults at increased cardiovascular risk and lowers LDL cholesterol in adults with hypercholesterolemia and in patients age 10 and older with heterozygous or homozygous familial hypercholesterolemia.
read more about evolocumab ...Evolocumab binds PCSK9 and prevents PCSK9 from binding LDL receptors on liver cells. This reduces LDL receptor degradation, increases the number of receptors available to clear LDL from the blood, and lowers circulating LDL cholesterol.
Evolocumab is used in adults at increased risk for major cardiovascular events and in adults with hypercholesterolemia. Current labeling also includes heterozygous familial hypercholesterolemia and homozygous familial hypercholesterolemia in adults and pediatric patients age 10 and older.
Adults at increased cardiovascular risk or with hypercholesterolemia and patients age 10 and older with heterozygous familial hypercholesterolemia use 140 mg subcutaneously every two weeks or 420 mg once monthly. Homozygous familial hypercholesterolemia starts at 420 mg monthly and can increase to 420 mg every two weeks after 12 weeks when response is inadequate.
Serious hypersensitivity reactions, including angioedema, have occurred with evolocumab. A history of serious hypersensitivity to evolocumab or its ingredients is a contraindication. Certain prefilled syringe and autoinjector presentations contain dry natural rubber in the needle cover, which can trigger allergic reactions in people sensitive to latex.
Evolocumab is a monoclonal antibody that inhibits PCSK9 and increases LDL receptor availability.
The labeled choices are 140 mg every two weeks or 420 mg once monthly.
Yes. Current labeling includes heterozygous and homozygous familial hypercholesterolemia from age 10.
Yes. Angioedema and other hypersensitivity reactions have been reported.
DailyMed - REPATHA (evolocumab) injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd61e902-166d-4aa6-9f3c-a18c1008d07e. Date Accessed September 30, 2026.
Evolocumab. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548469/. Date Accessed September 30, 2026.
Evolocumab Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a615043.html. Date Accessed September 30, 2026.
Evolocumab. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Evolocumab. Date Accessed September 30, 2026.
REPATHA (evolocumab) Prescribing Information. Amgen. https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english.pdf. Date Accessed September 30, 2026.